eISSN: 1897-4317
ISSN: 1895-5770
Gastroenterology Review/Przegląd Gastroenterologiczny
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank
2/2012
vol. 7
 
Share:
Share:
more
 
 
abstract:
Review paper

Reflux inhibitors – new therapy of gastroesophageal reflux disease

Grażyna Jurkowska
,
Agnieszka Świdnicka-Siergiejko
,
Andrzej Dąbrowski

Przegląd Gastroenterologiczny 2012; 7 (2): 57–62
Online publish date: 2012/05/22
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
The most relevant target for the treatment of refractory gastroesophageal reflux disease (GERD) is controlling the occurrence of transient lower esophageal relaxations (TLESR), which represent the main mechanism of all types of reflux. Drugs in development that have this mechanism of action are now described as reflux inhibitors. The most promising among these appear to be mGluR5 agonists and GABAB receptor agonists, which reduce the number of reflux episodes and improve reflux-related symptoms. Reflux inhibitors appear to have a potential role in the management of refractory GERD as add-on therapy in combination with PPI. Future studies will establish the safety and tolerability of the new anti-reflux therapy.
keywords:

gastroesophageal reflux, transient lower esophageal sphincter relaxation, GABA receptors, glutamate receptors

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe